Pharmacosmos A/S, a leader in iron deficiency treatments, has completed the acquisition of G1 Therapeutics, Inc., a commercial-stage oncology company, through a tender offer valued at approximately $405 million. Stockholders of G1 Therapeutics will receive $7.15 per share in cash. This acquisition allows Pharmacosmos to expand its product portfolio with Cosela (trilaciclib), a groundbreaking treatment for small cell lung cancer. The acquisition closed on September 18, 2024, with G1 Therapeutics merging into a subsidiary of Pharmacosmos and its shares being delisted from NASDAQ. This deal is expected to enhance the reach and impact of Cosela in the U.S. and internationally, aligning with Pharmacosmos’ growth strategy. The transaction involved financial advisement from MTS Health Partners and Centerview Partners, with legal support from Arnold & Porter Kaye Scholer LLP and Ropes & Gray LLP, among others.
Pharmaceuticals, Biotechnology, Healthcare,Denmark, United States
https://www.globenewswire.com/news-release/2024/09/18/2948213/0/en/Pharmacosmos-Group-and-G1-Therapeutics-Announce-Successful-Closing-of-Tender-Offer.html